Poseida Therapeutics, Inc.
PSTXNASDAQHealthcare
$9.50
+$0.00(+0.00%)
Market Cap$925933688
P/E Ratio—
52W High$9.67
52W Low$1.87
Poseida Therapeutics, Inc. (PSTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PSTX · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2024Report Date: Nov 7, 2024EPS Actual
$0.21
Est. -$0.41 · +151.2%
Revenue
$0.07B
Est. $0.02B · +237.6%
Fiscal Period
Q4 FY2024
FY ends December
Report Date
Nov 7, 2024
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
PSTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.41 | $0.21 | +151.2% | $0.07B | $0.02B | +237.6% |
| ▲ Q3 FY2024 | Aug 5, 2024 | -$0.43 | -$0.32 | +25.6% | $0.03B | $0.02B | +59.6% |
| ▲ Q2 FY2024 | May 14, 2024 | -$0.43 | -$0.25 | +41.9% | $0.03B | $0.01B | +141.2% |
| ▲ Q1 FY2024 | Mar 7, 2024 | -$0.36 | -$0.27 | +25.0% | $0.02B | $0.01B | +275.9% |
| ▼ Q4 FY2023 | Nov 9, 2023 | -$0.29 | -$0.35 | -20.7% | $0.01B | $0.01B | +14.8% |
| ▲ Q3 FY2023 | Aug 8, 2023 | -$0.53 | -$0.32 | +39.6% | $0.02B | $0.01B | +294.7% |
| ▼ Q2 FY2023 | May 9, 2023 | -$0.40 | -$0.45 | -12.5% | $0.01B | $0.01B | +10.4% |
| ▼ Q1 FY2023 | Mar 9, 2023 | $0.47 | -$0.39 | -183.0% | $0.01B | $0.06B | -83.9% |
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$0.21
EPS Est.
-$0.41
EPS Surpr.
+151.2%
Revenue
$0.07B
Q3 FY2024
Aug 5, 2024Beat
EPS Actual
-$0.32
EPS Est.
-$0.43
EPS Surpr.
+25.6%
Revenue
$0.03B
Q2 FY2024
May 14, 2024Beat
EPS Actual
-$0.25
EPS Est.
-$0.43
EPS Surpr.
+41.9%
Revenue
$0.03B
Q1 FY2024
Mar 7, 2024Beat
EPS Actual
-$0.27
EPS Est.
-$0.36
EPS Surpr.
+25.0%
Revenue
$0.02B
Q4 FY2023
Nov 9, 2023Miss
EPS Actual
-$0.35
EPS Est.
-$0.29
EPS Surpr.
-20.7%
Revenue
$0.01B
Q3 FY2023
Aug 8, 2023Beat
EPS Actual
-$0.32
EPS Est.
-$0.53
EPS Surpr.
+39.6%
Revenue
$0.02B
Q2 FY2023
May 9, 2023Miss
EPS Actual
-$0.45
EPS Est.
-$0.40
EPS Surpr.
-12.5%
Revenue
$0.01B
Q1 FY2023
Mar 9, 2023Miss
EPS Actual
-$0.39
EPS Est.
$0.47
EPS Surpr.
-183.0%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q3 FY2026 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q2 FY2026 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Q1 FY2026 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Q4 FY2025 | $-0.54 | $-0.54 | $-0.54 | 1 |
| Q3 FY2025 | $-0.49 | $-0.49 | $-0.49 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2024 | Nov 7, 2024 | +151.2% | $2.78 | $2.93 | +5.40% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +25.6% | $3.10 | $3.02 | -2.58% |
| ▲ Q2 FY2024 | May 14, 2024 | +41.9% | $2.81 | $2.92 | +3.91% |
| ▲ Q1 FY2024 | Mar 7, 2024 | +25.0% | $3.59 | $3.43 | -4.46% |
| ▼ Q4 FY2023 | Nov 9, 2023 | -20.7% | $2.28 | $2.20 | -3.51% |
| ▲ Q3 FY2023 | Aug 8, 2023 | +39.6% | $1.98 | $1.98 | +0.00% |
| ▼ Q2 FY2023 | May 9, 2023 | -12.5% | $3.38 | $3.40 | +0.59% |
| ▼ Q1 FY2023 | Mar 9, 2023 | -183.0% | $5.44 | $5.05 | -7.17% |
Q4 FY2024+5.40%
Report Date
Nov 7, 2024
EPS Beat/Miss
+151.2%
Price Before
$2.78
Price After
$2.93
Q3 FY2024-2.58%
Report Date
Aug 5, 2024
EPS Beat/Miss
+25.6%
Price Before
$3.10
Price After
$3.02
Q2 FY2024+3.91%
Report Date
May 14, 2024
EPS Beat/Miss
+41.9%
Price Before
$2.81
Price After
$2.92
Q1 FY2024-4.46%
Report Date
Mar 7, 2024
EPS Beat/Miss
+25.0%
Price Before
$3.59
Price After
$3.43
Q4 FY2023-3.51%
Report Date
Nov 9, 2023
EPS Beat/Miss
-20.7%
Price Before
$2.28
Price After
$2.20
Q3 FY2023+0.00%
Report Date
Aug 8, 2023
EPS Beat/Miss
+39.6%
Price Before
$1.98
Price After
$1.98
Q2 FY2023+0.59%
Report Date
May 9, 2023
EPS Beat/Miss
-12.5%
Price Before
$3.38
Price After
$3.40
Q1 FY2023-7.17%
Report Date
Mar 9, 2023
EPS Beat/Miss
-183.0%
Price Before
$5.44
Price After
$5.05
Avg Beat Reaction+0.45%
Avg Miss Reaction-3.36%
Beat Rate5 / 8 quarters
Largest Move-7.17% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PSTX ends December
Poseida Therapeutics, Inc. (PSTX) most recently reported earnings on November 7, 2024 for Q4 FY2024, posting EPS of $0.21 — beating the analyst consensus of $-0.41 by +151.2%. PSTX has beaten EPS estimates for 4 consecutive quarters. The next PSTX earnings date is expected around September 1, 2026.
Each quarter, investors track PSTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PSTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PSTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PSTX earnings · 5 questionsPoseida Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. PSTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PSTX historically reports after market close (AMC).
PSTX earnings datewhen is PSTX earningsPSTX next earnings datewhen does PSTX report earningsPSTX earnings calendar
▸ Source: FMP · Poseida Therapeutics, Inc. SEC filings · US GAAP · Poseida Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026